Pre-exposure Prophylaxis (PrEP) is a form of HIV prevention in which a HIV negative person at high risk of HIV infection takes daily antiretroviral medication to prevent HIV infection. Oral PrEP was first approved by the USA FDA in 2012 after which other countries followed. The Kenya Pharmacy and Poisons board approved the use of oral PreP in Kenya in December 2015. By April 2017, oral PrEP was approved by drug regulatory authorities in Australia, Canada, France, Israel, Kenya, Lesotho, Malawi, New Zealand, Peru, Scotland, South Africa, Swaziland, Switzerland, Taiwan, Tanzania, Thailand, United States of America (USA) and Zimbabwe3. Kenya will offer PrEP as part of HIV combination prevention for people at substantial ongoing risk of HIV infection. As part this is in line with the Kenya AIDS Strategic Framework 2014/15-2018/19 and the 2014 Kenya HIV Prevention Revolution roadmap, both of which identify PrEP as an evidence-based intervention delivered as part of a combination prevention approach, coupled with geographical prioritization, to achieve maximum impact in the reduction of HIV infections.